Arterial Remodeling Technologies ("ART") announced today that it has appointed Machiel Van Der Leest as its Chief Operating Officer, effective April 2008. Most recently, Van Der Leest was Director of R&D and Regulatory Affairs since May 2003 at Minvasys, which is focused on bifurcation treatment with dedicated devices.
PARIS (Business Wire EON) March 24, 2008 --
Arterial
Remodeling Technologies (“ART”)
announced today that it has appointed Machiel Van Der Leest as
its Chief Operating Officer, effective April 2008. Most recently,
Van Der Leest was Director of R&D and Regulatory Affairs since May 2003
at Minvasys, which is focused on bifurcation treatment with
dedicated devices.
ART
recently leased a manufacturing facility (20,000 square feet) as a
result of mastering proprietary polymer-based manufacturing technology
to produce bioresorbable
stents. The company’s bioresorbable
stents, which can be manufactured at very low cost, are designed to dismantle
in vivo over an optimized time horizon, thus allowing the body’s
natural arterial remodeling process to occur, which is normally
restricted by the deployment of permanent metallic stents.
“Given our approach of achieving temporary
stenting of a traumatized angioplasty site, we fully expect to benefit
greatly from Machiel Van Der Leest’s
understanding of the development, regulatory, clinical, manufacturing
and market dynamics of the stent sector,”
said Patrick Sabaria, founder, investor, and CEO of ART as
well as former Vice President, Europe, for J&J Interventional Systems,
where he introduced the world’s first
approved-for-marketing coronary stent, the Palmaz stent.
Prior to Minvasys, Van Der Leest was Director of R&D for Cathnet-Science
(Nycomed Amersham Medical Systems, or “NAMS”,
until July 2000) from Sept. 1999 through May 2003. He joined NAMS in
March 1999 as Project Engineer, directing the relocation of the company’s
manufacturing operations from France to Denmark. He is trilingual
(English, French, Dutch) and received a master’s
degree in Industrial Design Engineering from the Technical Univ. Delft,
Netherlands, in 1996.
About Arterial Remodeling Technologies (“ART”)
Arterial Remodeling Technologies (“ART”)
is developing bioresorbable peripheral and coronary polymer stents that
promote the natural remodeling of an injured artery after angioplasty.
The Company’s technology is based on
intellectual property originating from three esteemed institutions: the
Cleveland Clinic; the French national research institute, C.N.R.S.
(Centre National de Recherche Scientifique), Montpellier, France; and,
Necker University, Paris. To date, ART has raised €10
($14.2) million in venture capital from investors Matignon Technologies
and SGAM Alternative Investments.
MULTIMEDIA GALLERY http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5640010
Trackback URL: http://www.prweb.com/pingpr.php/Q3Jhcy1aZXRhLUluc2UtQ291cC1TdW1tLVplcm8=
|
